Screening and Prevention: Cervical Cancer

Primary Care - Clinics in Office Practice

Volumn 36, Issue 3, 2009, Pages 559-574

  Weinstein, Lara C ^a   Buchanan, Edward M ^a   Hillson, Christina ^a   Chambers, Christopher V ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cervical cancer; Cervical cancer pathogeneisis; Cervical cancer screening; HPV vaccine; Human papilloma virus

Indexed keywords

DIETHYLSTILBESTROL; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS DNA; WART VIRUS VACCINE;

CANCER MORTALITY; CANCER SCREENING; CARCINOGENESIS; CHLAMYDIASIS; CIGARETTE SMOKING; DEVELOPING COUNTRY; DISEASE COURSE; DNA DETERMINATION; FAMILY HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYSTERECTOMY; IMMUNE DEFICIENCY; MALIGNANT TRANSFORMATION; ORAL CONTRACEPTION; PAPANICOLAOU TEST; PHYSICIAN ATTITUDE; PREGNANCY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS IDENTIFICATION; WART VIRUS;

CERVIX UTERI; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY HEALTH CARE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 67651099059     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2009.04.010     Document Type: Review

References (49)

1. Global cancer facts and figures. Available at:. http://www.cancer.org/downloads/STT/Global_Cancer_Facts_andFigures_2007_rev.pdf Accessed August 22, 2008
2. Akers A.Y., Newmann S.J., and Smith J.S. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer 31 (2007) 157-181
3. Saraiya M., Ahmed F., Krishnan S., et al. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 109 2 (2007) 360-370
4. Downs L.S., Smith J.S., Scarinci I., et al. The disparity of cervical cancer in diverse populations. Gynecol Oncol 109 2008 (2008) S22-S30
5. Walboomers J.M.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
6. Ault K.A. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol (2006) Suppl:40470
7. Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
8. Safaeian M., Solomon D., and Castle P.E. Cervical cancer prevention - cervical screening: science in evolution. Obstet Gynecol Clin North Am 34 4 (2007) 739-760 ix
9. Cheng E., and Katz V.L. Fertilization and embryogenesis: meiosis, fertilization, implantation, embryonic development, sexual differentiation. In: Katz V.L., Lentz G.M., and Lobo R.A. (Eds). Comprehensive gynecology. 5th edition (2007), Mosby Elsevier, Philadelphia 12-14
10. Julian T.M. Cervix, vagina, and vulva: embryology, anatomy, physiology and histology. A manual of clinical colposcopy (1998), Parthenon, Nashville (TN) 16-28
11. Sellors J.W., and Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: a beginner's manual (2003), International Agency for Research on Cancer, Lyon 1-12 [Chapter 1]
12. Johnson B.A. The colposcopic examination. Am Fam Physician 53 (1996) 2473-2482 2487-8
13. Zur Hausen H. Papillomavirus infections: a major cause of human cancers. In: Zur Hausen H. (Ed). Infections causing human cancer (2006), Wiley-VCH, Weinheim 145-165
14. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 110 (2008) S4-S7
15. Oh S.T., and Laimins L.A. The molecular pathogenesis of human papillomavirus-associated cancer. In: Rohan T.E., and Shah K. (Eds). Cervical cancer - from etiology to prevention (2004), Kluwer Publishers, Norwell (MA) 101-118
16. Scheffner M., Werness B., Huiberegtse J., et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
17. Heck D., Yee C., Howley P., et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 89 (1992) 4442-4446
18. Crook T., Fisher C., and Vousden K. Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol 65 (1991) 505-510
19. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda system terminology for reporting results of cervical cytology. JAMA 287 16 (2002) 2114-2119
20. McCredie M.R.E., Sharples K.J., Paul C., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9 (2008) 425-434
21. Castellsague X., and Munoz N. Chapter 3. Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 31 (2003) 20-28
22. Samoff E., Koumans E., Markowitz L., et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 162 (2005) 668-675
23. Moreno V., Bosch F., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359 (2002) 1085-1092
24. Spitzer M. In vitro conventional cytology historical strengths and current limitations. Obstet Gynecol Clin North Am 29 4 (2002) 673-683
25. Runowicz C.D. Molecular screening for cervical cancer - time to give up pap tests?. N Engl J Med 357 16 (2007) 1650-1653
26. Arbyn M., Bergeron C., Klinkhamer P., et al. Liquid compared with conventional cytology. Obstet Gynecol 111 1 (2008) 167-177
27. Davey E., Barratt A., Irwig L., et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 367 9505 (2006) 122-132
28. Ronco G., Cuzick J., Pierotti P., et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomized controlled trial. BMJ 335 7629 (2007) 1053-1054
29. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188 (2003) 1383-1392
30. Wright T.C., Schiffman M., Solomon D., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103 2 (2004) 304-309
31. Saslow D., Runowicz C., Solomon D., et al. American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
32. ACOG. Cervical cytology screening. ACOG Practice Bulletin No. 45. Available at: (2003). http://www.acog.org/from_home/publications/press_releases/nr07-31-03-1.cfm Accessed February 26, 2009
33. USPSTF. Screening for cervical cancer. Available at: (Jan 2003). http://www.ahcpr.gov/clinic/uspstf/uspscerv.html Accessed February 26, 2009
34. Moscicki A.-B. The natural history of human papillomavirus infection measured by repeated DNA testing in adolescent and young women. J Pediatr 132 2 (1998) 277-284
35. Denny L., Boa R., Williamson A., et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 111 6 (2008) 1380-1387
36. Recommendations and reports. Guidelines for preventing opportunistic infections among HIV-infected persons 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Available at:. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5108a1.htm Accessed December 2, 2008
37. CDC. DES update: healthcare providers. Available at:. http://www.cdc.gov/des/hcp/information/daughters/risks_daughters.html Accessed December 21, 2008
38. Schiffman M., and Castle P.E. The promise of global cervical-cancer prevention. N Engl J Med 353 (2005) 2101-2104
39. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353 (2005) 2158-2168
40. Sankaranarayanan R., Madhukar Budukh A., and Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 79 (2001) 954-959
41. Wright T., Massad S., Dunton C., et al. The 2006 consensus guidelines for the management of women with abnormal cervical cancer screening. Am J Obstet Gynecol 197 4 (2007) 346-355
42. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
43. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 369 (2007) 1861-1868
44. Brown D. Future II Study Group. Quadrivalent HPV (type 6, 11, 16, 18) L1 VLP vaccine: updated 4 year analysis of cross-protection against CIN 2/3 AIS caused by oncogenic HPV types in addition to 16/18. 24th International Papillomavirus Conference & Clinical Workshop. Nov 3-9, 2007. Beijing, China.
45. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007) 1-24
46. Kim J.J., and Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 359 (2008) 821-832
47. Plummer M., Herrero R., Franceschi S., et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 14 (2003) 805-814
48. Almonte M., Albero G., Molano M., et al. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine 26S (2008) L16-L36
49. Zelmanowicz A., Schiffman M., Herrero R., et al. Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: Results from two studies conducted in Costa Rica and the United States. Int J Cancer 116 (2005) 599-605